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Objective: The main goal of this study is to determine the fliciency of the 
cardiomyoplasty procedure on patients with cardiomyopathy of different 
origins (ischemic and idiopathic origins). Method: Between June 1993 and 
August 1995, 24 patients underwent dynamic cardiomyoplasty with the left 
latissimus dorsi muscle in our institution. Early and midterm results, as 
weil as the changes in hemodynamics and functional status during foliow- 
up, were compared. Results: Early mortality rate was 20.8% (five patients). 
Concomitant coronary revascularization, a preoperative left ventricular 
ejection fraction below 20%, and a functional capacity of class 1V (inter- 
mittently) were associated with early mortality. The mean follow.up time 
was 17.3 months. Survival analysis (including early mortality) extending to 
the twenty-fourth month revealed no difference between the ischemic and 
idiopathic groups (55% vs 85%, respectively, p = 0.09). Functional status 
improved in the both groups. Ejection fractions were improved after 
cardiomyoplasty in all patients, regardless of their cause. Cardiac indices 
were higher 6 months after the operation. Changes in pulmonary capillary 
wedge pressure, peak pulmonary artery pressure, and lefl ventricular 
end-diastolic volume were not significant. Condusion: Although cardio- 
myoplasty improves functional capacity and hemodynamics in patients with 
both idiopathic and ischemic cardiomyopathy, the idiopathic group is 
thought to achieve optimal benefit with regard to lower complication rates 
and lower early mortality expectancy owing to the absence of concomitant 
coronary revascularization. (J Thorac Cardiovasc Surg 1997;113:173-81) 
S ince the first clinical application of cardiomyo- plasty in 1985,1 determining the patient group 
expected to have the maximum benefit after the 
procedure has been a major concern in many clinical 
and experimental trials. Although dynamic cardio- 
myoplasty has been performed on more than 500 
patients and results in groups with different causes 
for cardiomyopathy ave been reported, the efficacy 
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of dynamic cardiomyoplasty in the separate groups 
still needs to be clarified. In this study, we compared 
the early and midterm courses of our patients with 
ischemic and idiopathic origins for cardiomyopathy 
with regard to operative mortality, survival, func- 
tional capacity improvement, and certain clinical 
and hemodynamic parameters. 
Patients and methods 
Between June 1993 and August 1995, 24 patients un- 
derwent dynamic ardiomyoplasty with the left latissimus 
dorsi muscle in our institution. Two of the patients were 
female. The mean age was 43 + 9 years. All patients were 
in New York Heart Association functional class III (six 
patients had been admitted to the hospital with class IV 
symptoms and had improved to class III with vigorous 
medical treatment). Our patient population was divided 
into two subgroups depending on the causes of the 
disease: ischemic ardiomyopathy group (11 patients) and 
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Table I. Preoperative data 
Ischemic Idiopathic Total 
Patient No. 11 13 24 
Female/male 0/11 2/11 2/22 
Mean age (yr) 43 + 6 42 _+ 11 43 -+ 9 
NYHA class III 8 10 18 
NYHA class IV 3 3 6 
(intermittent) 
Average C/T ratio 0.60 0.60 0.60 
Major Holter 4 5 9 
arrhythmia 
LVEF (MUGA) (%) 23 -+ 4 27 _+ 4 25 -+ 4 
PCWP (mm Hg) 17 -+ 4 18 _+ 10 18 -+ 7 
Cardiac index 2.38 -+ 0.2 2.44 - 0.3 2.42 -+ 0.3 
(L/min/m 2) 
C/T ratio, Cardiothoracic ratio; LVEF (MUGA), left ventricular ejection 
fraction determined by radionuclide ventriculography; NYHA, New York 
Heart Association; PCWP, pulmonary capillary wedge pressure. 
idiopathic ardiomyopathy group (13 patients). Ischemic 
cardiomyopathy was diagnosed by the occurrence of a 
dilated cardiomyopathy and documented coronary artery 
stenosis or typical enzymatic and electrocardiographic 
criteria for a previous myocardial infarction. The diagno- 
sis of idiopathic dilated cardiomyopathy was assigned only 
to patients with angiocardiographically normal coronary 
arteries and no other obvious cause for left ventricular 
dysfunction. There was no statistically important differ- 
ence between the two groups regarding age and preoper- 
ative clinical or hemodynamic condition (Table I). Oper- 
ative indications and contraindications and the surgical 
technique were the same as described by Carpentier and 
Chachques and their associates. 2' 3 
The operative procedure was left latissimus dorsi dy- 
namic eardiomyoplasty. In four patients, dynamic ardio- 
myoplasty was supplemented with concomitant coronary 
artery bypass grafting. The operation was done on the 
beating heart without the use of extracorporeal circula- 
tion. Our indication for performing the concomitant cor- 
onary artery bypass procedure was angiographieally im- 
portant coronary stenoses associated with stable angina. 
In patients who had ischemic ardiomyopathy plus angina, 
we added coronary revascularization to the standard 
cardiomyoplasty procedure with the expectation of im- 
provement due to perfusion of possibly hibernating local 
ventricular musele and improvement of the symptoms 
(i.e., life quality) after the operation. 
The use of prophylactic ntraaortic balloon (lAß) sup- 
port to improve patient stability during the procedure and 
in the early postoperative course seemed appropriate. 
Therefore, in the last 11 patients (two of the ischemic 
group and nine of the idiopathic group), we routinely 
inserted an IAB just after the induction of anesthesia. IAB 
counterpulsation lasted 1 or 2 days after the operation. 
A Medtronic Cardiomyostimulator (model SP 1005A 
and model 4710; Medtronic, Inc., Minneapolis, Minn.) 
with a stimulation protocol described by Chachques, 
Grandjean, and Carpentier a was used. 
The mean follow-up time for the total cardiomyoplasty 
group was 17.3 months. Statistical analyses were per- 
formed by a certified statistician. The tests used for each 
item are described in the related part of the Results 
section. Survival curves are estimated by means of the 
Kaplan-Meier method and compared by means of the log 
rank test. Because functional class is on a scale from I to 
IV, it is unlikely that the necessary distributional ssump- 
tions for a standard variance analysis will hol& Similarly, 
inadequate number of cases on the basis of ischemic and 
idiopathic subgroups necessitated nonparametric tests for 
comparison of the ejection fractions and functional status 
at certain fõllow-up periods. Therefore the Wilcoxon 
matched-pairs signed-rank test was used for performing 
pairwise comparisons of ejection fractions and functional 
capacities during the follow-up period. With this test we 
compared all possible pairs during a given follow-up 
period (e.g., preoperative to third postoperative month, 
preoperative to sixth postoperative month, third to sixth 
postoperative month) for the total group (appendix). 
Comparisons of these data between the ischemic and 
idiopathic groups at each follow-up period were per- 
formed with the Mann-Whitney U test. With this test we 
compared the differences from the baseline (preopera- 
tive) values for the ejection fractions or average functional 
classes from the two subgroups (ischemic and idiopathic) 
at the same follow-up period. For this purpose, the 
ejection fraction or functional class values obtained at 
postoperative months 3, 6, 12, and 24 were subtracted 
from the preoperative value. The changes from the pre- 
operative period for each postoperative interval were 
obtained for both groups (idiopathic and ischemic). Then, 
using the Mann-Whitney U test, we compared these 
adjusted values (the change from the preoperative period) 
from those two subgroups (e.g., the difference at the third 
postoperative month for the idiopathic group was com- 
pared with that of the ischemic group). Because this is a 
multiple comparison situation (with ten comparisons in 
the total group between the periods during the follow-up 
and four between the subgroups at the same period), an 
adjustment for the p value was necessary. An adjusted p
value (c 0 may be calculated as follows: For the pairwise 
comparisons for the ejection fraction or functional class 
improvement in the total group during follow-up (i.e., 
Wilcoxon matched-pairs signed-rank test), a = 0.05 / 10 = 
0.005. For the comparisons between the ischemic and 
idiopathic subgroups at each foUow-up eriod (i.e., Mann- 
Whitney U test), a = 0.05 / 4 = 0.013. Any significance 
depending on these adjusted p values is indicated in the 
appendix. 
Univariate analysis for determining the factors associ- 
ated with early hospital mortality was performed with 
Fisher's exact est. Proportions uch as mortality rates are 
compared with the ~ß test. A p value equal to or smaller 
than 0.05 was considered as statistically important. 
Results 
Mortality. There were five early and two late 
deaths (30-day hospital mortality was 20.8%). Early 
hospital mortality rate was 36.3% in the ischemic 
group and 7.6% in the idiopathic group. The differ- 
ence between these two mortality rates did not reach 
statistical significance (p = 0.11). 
As seen in Table II, in the early postoperative 
period, one patient from the idiopathic group died 
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Table II. Mortality causes 
Ischemic Idiopathic Total 
Early 
Low cardiac output 2* 1 3 
Cerebral embolism 1 - -  1 
Sepsis 1 * - -  1 
Late 
Congestive heart failure 1" 1 2 
(*)Patients with associated coronary revascularization. 
of low cardiac output. Four patients from the isch- 
emic group died (two of low cardiac output, orte of 
cerebral embolism, and another of Klebsiella pneu- 
monia and sepsis). Three of those four patients with 
ischemic cardiomyopathy who died in the early 
postoperative period had also undergone concomi- 
tant coronary bypass grafting. 
Postoperative complieations. Early postoperative 
complications are summarized in Table III. Compli- 
cations were more frequent in the ischemic group. 
Apart from the prophylactic use in the last 11 
patients, an IAB was inserted in the early postoper- 
ative period in four additional patients for the 
treatment of low cardiac output. 
Events in the follow-up period. Two deaths oc- 
curred in the follow-up period. One patient with 
cardiomyopathy of ischemic origin (the last surviv- 
ing patient with concomitant coronary bypass) died 
of biventricular failure on postoperative day 110. 
Another patient (with idiopathic origin) died of 
cardiac failure on postoperative day 247. This pa- 
tient had had a preoperative l ft ventricular ejection 
fraction of 11% and a left ventricular end-diastolic 
volume of 400 rel. One patient with ischemic ar- 
diomyoplasty was hospitalized 1 year after the op- 
eration with atrial fibrillation refractory to medical 
therapy. Later his myostimulator was switched from 
1:2 mode (latissimus dorsi muscle contracts with 
every second heartbeat) to 1:1 mode and sinus 
rhythm was restored. Apart from these, no other 
patient was hospitalized for congestive heart failure 
in the follow-up period. 
Ineremental risk factors for early hospital mor- 
tality. Univariate analysis (Fisher's exact test) was 
performed for the total group to determine the 
parameters a sociated with early hospital mortality. 
Age, type of cardiomyopathy (ischemic or idiopath- 
ic), concomitant coronary revascularization, prophy- 
lactic IAB support, a preoperative l ft ventricular 
ejection fraction below 20%, preoperative spiromet- 
ric data below 50% of predicted, severe preopera- 
tive rhythm disturbänces, preoperative functional 
classes (i.e., class III vs intermittent class IV), and 
Table III. Early nonfatal postoperative 
complications 
Ischemic 
group 
O~ = 7) 
No. % 
Idiopathic 
group 
(n = 12) 
No. % 
Low cardiac output 3 42.8 1 8.3 
Rhythm disturbances 
Atrial fibrillation 2 28.5 1 8.3 
Ventricular fibrillation 2 28.5 2 16.6 
Frequent VPCs 4 57 1 8.3 
Wound infection 2 28.5 1 8.3 
VPCs, Ventricular premature contractions. 
Table IV. Factors associated with early hospital 
mortality: Univariate analysis 
p Value 
LVEF below 20% 
Class IV (intermittent) functional capacity 
Concomitant coronary revascularization 
Age 
Severe rhythm disturbances 
Left ventricular end-diastolic pressure 
Ischemic etiology 
Spirometric data below 50% of predicted 
Prophylactic IABP 
0.0013" 
0.018' 
0.018" 
0.4867 
0.432t 
0.09t 
0.111t 
0.452t 
0.2157 
LVEF, Left ventricular ejection fraction;/ABP, intraaortic balloon coun- 
terpulsation. 
*Statistically significant. 
tNot significant. 
preoperative l ft ventricular end-diastolic pressures 
were the factors to be analyzed for any association 
with early mortality. Univariate analysis indicated 
the associated coronary bypass procedure (p -- 
0.018), a class IV functional capacity (intermittent- 
ly) (p = 0.018), and a preoperative l ft ventricular 
ejection fraction below 20% (p = 0.0013) as the 
factors associated with early mortality (Table IV). 
Survival comparison. Kaplan-Meier analysis (log 
rank) was used for survival comparisons. Operative 
mortality is included in this analysis. A p value less 
than or equal to 0.05 was considered as statistically 
important. Survivals for each group (ischemic, idio- 
pathic, and combined) are presented in Fig. 1. 
Kaplan-Meier survival analysis revealed no statis- 
tically important difference between the ischemic and 
the idiopathic groups (p = 0.09). At postoperative 
month 24, survivals were 55% versus 85%, respectively 
(Fig. 1). Survival for the total group was 71%. 
Comparison of preoperative and postoperative 
hemodynamic data 
Ejection fraction. The Wilcoxon matched-pairs 
signed-rank test was used for pairwise comparisons 
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Fig. 1. Postoperative survival (including early hospital mortality) in patients with ischemic or idiopathic 
cardiomyopathy. Patient numbers entering each period from each group are described below the 
illustration. Idiop., Idiopathic; Ische., ischemic. 
Table V. Hemodynamics 
Postop. 
Preop. 3 mo 6 mo 12 mo 24 mo 
Patient No. 24 19 18 16 10 
LVEF (MUGA) (%) 
Total group 25 -+ 4 34 -+ 10 34 _+ 6 32 -+ 5 35 + 6 
Ischemic 23 -+ 4 32 -+ 9 34 _+ 7 28 + 3 31 +- 4 
Idiopathic 27 + 4 36 -+ 11 35 -+ 4 36 + 4 39 -+ 7 
LVEDVI (ml/m 2) 115 -+ 14" 121 _+ 16" 
LVEF (MUGA), Left ventricular ejection fraction determined by radionuclide ventriculography; LVEDVI, left ventricular end-diastolic volume index. 
*p = 0.453 (not significant). 
of ejection ffactions during the follow-up period in 
the total group. A statistically important improve- 
ment was evident in the third, sixth, twelfth, and 
twenty-fourth postoperative months (see the appen- 
dix for exact p values) when compared with preop- 
erative values (Table V and the appendix). The 
Mann-Whitney U test was used to compare the 
ejection fraction changes between the ischemic and 
idiopathic subgroups ffom the preoperative period 
onward. No significant difference was found at any 
follow-up period (appendix). In other words, ejec- 
tion fraction trends for the ischemic and idiopathic 
groups were roughly parallel in the first 2 years. 
Cardiac index. We compared the preoperative and 
postoperative (sixth postoperative month) values ob- 
tained with cardiac atheterization. According to the 
Wilcoxon matched-pairs signed-rank test, the patients' 
cardiac indices improved after cardiomyoplasty (p = 
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0.03, Table VI). There were no important dilferences 
between the subgroups (p = 0.857). 
Other comparative data. Pulmonary capillary wedge 
pressure, peak pulmonary artery pressure, and left 
ventricular end-diastolic volume (Table V) were not 
significantly affected after the operation, according to 
the Wilcoxon matched-pairs signed-rank test. 
Funetional elass. The Wilcoxon matched-pairs 
signed-rank test was used for pairwise comparisons 
of average functional classes during the follow-up 
period in the total group. A statistically important 
improvement was evident in the third, sixth, twelfth, 
and twenty-fourth postoperative months when com- 
pared with preoperative functional classes (see the 
appendix for exact p values). A comparison between 
the ischemic and idiopathic groups was done with 
the Mann-Whitney U test at each follow-up period, 
as explained in the Patients and methods ection. No 
significant difference between the subgroups was 
found at any postoperative time interval (appendix). 
Preoperative mean functional class of 3.2 was 
improved to 1.3 after 2 years. This means an im- 
provement of 60% in average functional class (Figs. 
2 and 3). 
Discussion 
Various surgical methods have been proposed to 
treat end-stage heart disease. Transplantation and 
artificial organs have been used in these patients in 
limited numbers because of the scarcity of available 
donor organs for transplantation and clotting prob- 
lems in artificial organs. Unavailability of donor organs 
resulting from socioeconomi¢ problems and the lack of 
adequate infrastructure and organization strictly limit 
transplantation possibilities, especially in Turkey. 
The idea of cardiomyoplasty is to wrap the latis- 
simus dorsi muscle around the heart and to bring 
extra support both passively and dynamically while 
simultaneously contra¢ting the muscle with the myo- 
cardium to augment he generated power. Contri- 
bution of the latissimus dorsi to cardiac activity may 
vaPy with the nature of the heart disease. We 
compared the outcome of patients undergoing car- 
diomyoplasty for two different ypes of cardiomyop- 
athy to investigate the eificacy of the procedure. One 
group consisted of 11 patients with ischemic ardio- 
myopathy and the other consisted of 13 patients 
with idiopathi¢ cardiomyopathy. 
Age, prophylactic IAB pumping, preoperative spi- 
rometric data below 50% of predicted, severe pre- 
operative rhythm disturbances, and preoperative 
left ventricular end-diastolic pressures were found 
to be the factors having no important influence on 
Table VI. Cardiac index (L/m2/min) 
lschemic Idiopathic Total 
subgroup subgroup group 
Preop. 2.38 + 0.2 2.44 _+ 0.3 2.42 _+ 0.3 
Postop. (6 mo) 2.60 -+ 0.5 2.68 _+ 0.7 2.67 -+ 0.6 
p Value 0.03 0.04 0.04 
early mortality. Univariate analysis indicated an 
associated coronary bypass procedure, a class IV 
functional capacity (intermittently), and a preoper- 
ative left ventricular ejection fraction below 20% as 
the factors being associated with early mortality. 
Our relatively high rate of early mortality in the 
ischemic group might have been influenced by the 
associated coronary artery bypass procedure in this 
group. For more detailed information, logistic re- 
gression analysis could be performed after a suffi- 
cient number of cases for this analysis was obtained. 
Many studies emphasize various incremental risk 
factors for early mortality. In a study by Magovern 
and assoeiates, 5 biventricular failure (especially with 
a right ventricular ejection fraction lower than 40%) 
was described as an important risk factor for early 
mortality. Biventricular failure was emphasized as a 
contraindication for cardiomyoplasty in the study by 
Carpentier and colleagues. 2 
In our patient population, the course in the 
intensive care unit was more complicated for the 
ischemic group than for the idiopathic group. Fur- 
thermore, concomitant surgery is frequently re- 
quired in patients with ischemic heart disease, bring- 
ing additional problems that infiuence both mortality 
and morbidity. Carpentier and associates 2 docu- 
mented that concomitant surgery is an incremental 
risk factor in the cardiomyoplasty population. Lorusso 
and associates 6 operated on nine patients without any 
associated procedure, and orfly one of their patients 
died--as a result of respiratory distress syndrome in 
the first postoperative month. However, in some re- 
ports early mortality was found to be independent of
associated surgical procedures. 7 
Minimal doses of inotropic drugs in combination 
with the perioperatively inserted IAB is logical in 
the cardiomyoplasty population, a group in which 
high perioperative risk is anticipated. Although sta- 
tistical analysis revealed no effect on early mortality, 
prophylactic IAB support during the operation and 
for the first 48 hours of the postoperative p riod still 
seems logical to provide a smoother postoperative 
course and a more comfortable course during the 
surgical procedure. Of the last 11 patients with a 
prophylactic, preoperatively inserted IAB, only one 
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Fig. 2. The course of functional classes in the idiopathic group. NYHA, New York Heart Association. 
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Fig. 3. The course of functional classes in the ischemic group. NYHA, New York Heart Association. 
patient died (of a noncardiac event--sepsis). On the 
other hand, of the 13 patients without his prophylactic 
measure, four died (three of low cardiac output). 
Therefore we advise the prophylactic perioperative 
insertion of an IAB as a routine procedure. However, 
especially in patients with ischemic ardiomyopathy, a 
full Doppler evaluation of the lower extremity periph- 
eral arteries hould be done before considering such 
prophylactic use of the IAB, because of the extensive 
nature of the atherosclerotic process. 
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Follow-ups extending to the twenty-fourth post- 
operative month showed no statistically important 
difference in the Kaplan-Meier survival analysis 
between the ischemic and idiopathic groups. 
Left ventricular ejection fractions are improved 
after cardiomyoplasty. Between the subgroups, post- 
operative trends in the ejection fractions were roughly 
parallel during the follow-up period. Improvement in
the ejection fractions without significant change in left 
ventricular end-diastolic volumes uggested some ben- 
eficial effects of cardiomyoplasty. 
A statistically important improvement in func- 
tional class (an improvement of 60%) for the total 
cardiomyoplasty population was established. This 
improvement did not differ in degree for the two 
etiologic subgroups. 
Although no differences in objective (ejection 
fraction) or subjective (functional status) criteria 
were detected uring the postoperative follow-up 
period between the two groups, the idiopathic group 
is thought o obtain optimal benefit with regard to 
lower early complication rates and lower early mor- 
tality expectancy. The advantage is that these pa- 
tients do not need concomitant coronary revascular- 
ization, which is associated with early mortality. 
In our study, the early mortality rate for the 
ischemic group was 36.3% whereas it was 7.6% in 
the idiopathic group. This difference did not 
reached statistical significance with Fisher's exact 
test (p = 0.11), which was used for the analysis of 
the factors to be associated with early mortality in 
this study. On the other hand, when another test 
(comparison of two proportions, z-test) is done, the 
p value reached 0.04. This difference may be due to 
the relatively low number of cases, and tests must be 
repeated after more cases are available for analysis. 
Thus bettet results may be expected in the idio- 
pathic group in terms of early mortality and compli- 
cation rates. This could probably be attributed to the 
difference in nature between the two etiologic on- 
ditions. Metabolic imaging studies in the ischemic 
cardiomyopathy group had revealed large defects 
covering more than 15% of the cross-sectional area of 
the left ventricle; however, such large defect zones had 
only rarely been observed in nonischemic cardiomyop- 
athies, s Residual function of the heart may be an 
important factor in the overall performance of the 
dynamic cardiomyoplasty. 9 This might explain why 
dynamic ardiomyoplasty has been reported to be less 
etticient in such severe myocardial dysfunction. 
In the light of the current study, we believe that 
risk is greater in ischemic than in idiopathic ardio- 
myopathy as a result of the pathophysiologic differ- 
ences, as well as additional risks from the expected 
concomitant procedures (i.e., coronary bypass graft- 
ing). Hence higher mortality and morbidity could be 
expected in the early postoperative period. How- 
ever, after a certain period of convalescence, the 
courses for the two groups became parallel. The data 
contain only the midterm restdts, and later follow-up 
will supply more information about the long-term 
prognosis of patients with different underlying causes. 
In conclusion, in out 24-patient cardiomyoplasty 
group, we found an improvement in ejection frac- 
tions and in functional classes at the end of a 
follow-up period of 24 months. Survivals did not 
differ between the idiopathic and the ischemic sub- 
groups. The current study considers early and mid- 
term results. Because of the progressive nature of 
the disease, long-term results must also be obtained 
to clarify obscured points and perhaps to accentuate 
the possible differences between the etiologic sub- 
groups that are currently not apparent. 
Addendum 
Since the submission of this manuscript, seven more 
patients have successfully undergone dynamit ¢ardiomy- 
oplasty in our institution. Hence our cardiomyoplasty 
experience has currently reached 31 cases. However, 
because the statistical interpretation ofthese patients has 
not been performed at this time, related data are not 
included in this study. 
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Append ix .  Statistical analysis o f  the fol low-up data 
Compared Statistical test used for the 
parameter Comparison Cornpared periods p Value Significance* analysis 
Preop.-3 mo Wileoxon matehed-palrs Ejection fraction 
(objective) slgned-rank test 
Wilcoxon matched-patrs 
signed-rank test 
Wilcoxon matched-palrs 
slgned-rank test 
Wilcoxon matched-pmrs 
signed-rank test 
Wilcoxon matched-pmrs 
slgned-rank test 
Wilcoxon matched-palrs 
slgned-rank test 
Wilcoxon matched-pmrs 
signed-rank test 
Wilcoxon matched-palrs 
slgned-rank test 
Wilcoxon matched-pmrs 
signed-rank test 
Wilcoxon matched-pmrs 
signed-rank test 
Mann-Whitney U test 
Functional status 
(subjective) 
Within subject (total 
group, during follow-up) 
Between subject (ischemic 
vs idiopathic) 
Within subject (total 
group, during follow-up) 
Between subject (ischemic 
vs idiopathic) 
Preop.~5 mo 
Preop.-12 mo 
Preop.-24 mo 
3 mo-6 mo 
3 mo-12 mo 
3 mo-24 mo 
6 mo-12 mo 
6 mo-24 mo 
12 mo-24 mo 
Preop.-3 mo difference between 
ischemic and idiopathic 
Preop.--6 mo difference between 
ischemic and idiopathic 
Preop.-12 mo difference be- 
tween ischemic and idiopathic 
Preop.-24 mo difference be- 
tween ischemic and idiopathic 
Preop.-3 mo 
Preop.-6mo 
Preop.-12 mo 
Preop.-24 mo 
3 mo-6 mo 
3 mo-12 mo 
3 mo-24 mo 
6 mo-12 mo 
ó mo-24 mo 
12 mo--24 mo 
Preop.-3 mo difference between 
ischemic and idiopathic 
Preop.--6 mo difference between 
ischemic and idiopathic 
Preop.-12 mo difference be- 
tween ischemic and idiopathic 
Preop.-24 mo difference be- 
tween ischemic and idiopathic 
0.0009 Significant 
0.0007 Significant 
0.001 Significant 
0.0031 Significant 
0.7333 Nonsignificant 
0.2719 Nonsignißcant 
0.3139 Nonsignificant 
0.2213 Nonsignificant 
0.398 Nonsignificant 
0.1551 Nonsignificant 
0.6723 Nonsignificant 
0.3696 Nonsignificant 
0.0486 Nonsignificant 
0.4647 Nonsignificant 
0.0001 Significant 
0.0002 Significant 
0.0007 Significant 
0.0031 Signißcant 
0.3613 Nonsignificant 
0.593 Nonsignificant 
0.3173 Nonsignificant 
0.593 Nonsignificant 
1 Nonsignificant 
1 Nonsignifieant 
0.2697 Nonsignificant 
0.3511 Nonsignificant 
0.0976 Nonsignificant 
0.0312 Nonsignificant 
Mann-Whimey U test 
Mann-Whitney U test 
Mann-Whitney U test 
Wilcoxon matched-patrs 
signed-rank test 
Wilcoxon matched-palrs 
signed-rank test 
Wilcoxon matched-palrs 
signed-rank test 
Wilcoxon matched-palrs 
slgned-rank test 
Wilcoxon matched-palrs 
signed-rank test 
Wilcoxon matched-palrs 
signed-rank test 
Wilcoxon matched-pmrs 
slgned-rank test 
Wilcoxon matched-palrs 
signed-rank test 
Wilcoxon matched-palrs 
slgned-rank test 
Wilcoxon matched-palrs 
signed-rank test 
Mann-Whitney U test 
Mann-Whitney U test 
Mann-Whitney U test 
Mann-Whitney U test 
Preop., Preoperative; 3 mo, postoperative third month; 6 mo, postoperative sixth month; 12 mo, postoperative twelfth month; 24 mo, postoperative 
twenty-fourth month. 
*Significance is determined according to the p value adjustment. Adjusted p value = 0.05/10 = 0.005 for the Wilcoxon matched-pairs signed-rank test and 
0.05/4 = 0.013 for the Mann-Whitney U test. See Patients and methods in text for details. 
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Commentary  
This arti¢le reports the institutional experience of the 
authors with cardiomyoplasty. It is of interest because it 
indicates how the results claimed by the pioneering cen- 
ters can be reproduced by others. The authors also 
attempted to analyze the outcome using the cause of 
¢ardiomyopathy (ischemic vs idiopathic) as a variable. 
However, such institutionally based data also suffer from 
some limitations. The obvious one in this series is the 
small sample size, which reduces the statistical power. For 
example, the hospital mortality for the ischemic group was 
36.3%, almost five times that of 7.6% for idiopathic group, 
but the difference did not reach statistical significance 
(p = 0.11). Likewise, they reported no difference in 24- 
month survival (p = 0.09) between these two groups, even 
though the survivals were 55% versus 85%. Another weak- 
ness with smaU sample size is the ditficulty in carrying out 
subgroup analysis. In this series, 24 patients were divided 
into two groups: 13 in the idiopathic and 11 in the ischemic 
group. In fact, the ischemic group contains four patients who 
underwent concomitant coronary revascularization, an im- 
portant confounding factor that was not analyzed, perhaps 
because the number of patients was too small to do so. 
It could be of interest o compare these findings with 
the results available in the larger database maintained by 
Medtronie Inc. for the Worldwide Cardiomyoplasty Group. 
As shown in Fig. 1, 216 patients with idiopathic ardiomy- 
opathy had a survival curve similar to that of 130 patients 
whose heart failure was due to ischemia, although those with 
multivessel diseases may have higher postoperative risk. In 
contrast, the 45 patients who had concomitant coronary 
bypasses had a significantly higher risk of perioperative 
death. Preoperative New York Heart Associatiou class IV 
was a significant risk factor. Unlike this series from Turkey, 
however, most coronary bypasses were carried out with 
extracorporeal circulatory support, while cardiomyoplasty 
procedures are being done with pump standby. 
In reviewing not only the survival, but also the functional 
and hemodynamic outcome, one wonders how they compare 
with alternate therapies, uch as conventional medical man- 
agement for heart failure. A prospective randomized trial to 
answer this is still in progress in North America. However, 
results of the phase II trial, in which a medically treated 
matched reference group served as control, are now avail- 
able and will be published shortly. 1For example, the hospital 
mortality was 12%, as compared with 20.8% reported in this 
series, and postoperative functional improvement was simi- 
lar. Ejection fraction increases 6 and 12 months after the 
operation were statistically significant, but of lesser magni- 
tude. Concomitant procedures and preoperative New York 
Heart Association class IV were avoided in the phase II 
study, so that some of the differences noted may be related to 
case selection. Together with often unique individual insti- 
tutional experience, such multicenter studies, with their 
greater statistical power, contribute to our understanding 
and progress of cardiomyoplasty, and other novel surgical 
innoivations. 
Ray C.-J. Chiu, MD, PhD 
McGill University 
Montreal, Quebec, Canada 
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Fig. 1. Survival of idiopathic versus ischemic group. 
